2002 Progress Report: Study of Phthalates in Pregnant Woman and ChildrenEPA Grant Number: R829436
Title: Study of Phthalates in Pregnant Woman and Children
Investigators: Swan, Shanna Helen , Calafat, Antonia , Drobnis, Erma , Lasley, Bill L. , Redmon, Bruce , Sparks, Amy , Wang, Christina
Current Investigators: Swan, Shanna Helen , Calafat, Antonia , Kruse, Robin , Lasley, Bill L. , Redmon, Bruce , Sparks, Amy , Wang, Christina
Institution: University of Missouri - Columbia , University of California - Davis , University of California - Los Angeles , University of Iowa , University of Minnesota
Current Institution: University of Rochester , CDC , Harbor-UCLA Medical Center , University of California - Davis , University of Iowa , University of Minnesota , University of Missouri - Columbia
EPA Project Officer: Hunt, Sherri
Project Period: August 1, 2001 through January 31, 2005 (Extended to July 31, 2007)
Project Period Covered by this Report: August 1, 2001 through January 31, 2002
Project Amount: $2,779,164
RFA: Endocrine Disruptors: Epidemiologic Approaches (2001) RFA Text | Recipients Lists
Research Category: Economics and Decision Sciences , Health , Safer Chemicals , Endocrine Disruptors
The objective of this research project is to assess the risks posed by environmental phthalate levels to reproductive health by addressing the following issues:
· Does in utero phthalate exposure alter breast and genital development?
· How do infants' pre- and postnatal sensitivity to phthalates compare?
· What are major sources of phthalate exposure for pregnant women and infants?
· Do phthalate metabolite levels vary with ethnicity and geography?
· Do genital and breast measurements vary with ethnicity and geography?
· How is phthalate metabolism altered by pregnancy?
During Year 1 of the project, we: (1) piloted all phases of the study; (2) developed all study instruments, protocols, and databases; and (3) examined 94 subjects as of September 28, 2002.
During Year 2 of the project, we expect to: (1) conduct 275 first visits (in California, Missouri, Minnesota, and Iowa); (2) conduct 125 second visits (in California, Missouri, and Minnesota); (3) use intensive tracing methods to locate subjects that have not responded to telephone calls and initial mailings; (4) begin urinary assays for follicle stimulating hormone; (5) complete at least one manuscript on methods used for physical exam; and (6) obtain descriptive statistics on genital and breast measurements in first 300 subjects, overall and stratified by ethnicity and center.